D. Kalev

Abstract S4-07: BELLE-3: A phase III study of buparlisib + fulvestrant in postmenopausal women with HR+, HER2–, aromatase inhibitor-treated, locally advanced or metastatic breast cancer, who progressed on or after mTOR inhibitor-based treatment

P. Lønning, T. Decker, A. Leo, 2017 .

Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial.

P. Lønning, S. Johnston, T. Decker, 2018, The Lancet. Oncology.

Cell adhesion molecules in pleural effusions with different etiology

I. Micheva, G. Georgiev, D. Kalev, 1996 .

FIRST LINE 5!FU!BASED CHEMOTHERAPY WITH/ WITHOUT BEVACIZUMAB FOR METASTATIC COLORECTAL CANCER: ONE CENTER EXPERIENCE RESULTS

T. Chervenkov, N. Conev, I. Donev, 2015 .

Namodenoson in Advanced Hepatocellular Carcinoma and Child–Pugh B Cirrhosis: Randomized Placebo-Controlled Clinical Trial

P. Fishman, T. Ciuleanu, A. Croitoru, 2021, Cancers.

CECOG experts’ recommendations on the use of denosumab in the prevention of skeletal-related events in bone metastases of lung cancer

R. Gaafar, T. Brodowicz, D. Aebersold, 2013, memo - Magazine of European Medical Oncology.

2-year single center clinical experience in patients with colon cancer stage II and III receiving adjuvant chemotherapy

N. Conev, I. Donev, D. Kalev, 2015 .

Cemiplimab treatment of squamous cell carcinoma in a patient with severe recessive dystrophic epidermolysis bullosa

D. Kalev, D. Dimitrov, M. Karamanliev, 2023, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

TROUSSEAU SYNDROME AS AN INITIAL MANIFESTATION OF PANCREATIC ADENOCARCINOMA : CASE REPORT

R. Georgiev, A. Kaprelyan, D. Kalev, 2014 .